A Phase 3 interventional study of Adalimumab and Adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 87 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-26.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 15th largest by enrollment, is one of 4 that started in 2000, is one of 36 in phase 3, and was the 2nd registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 619 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 7th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2000, is one of 14 in phase 3, and was the 2nd registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.
This was a 10-year study which had an initial 52-week, double-blind, placebo-controlled phase followed by an open-label extension phase up to 9 years in duration. Data were analyzed for the double-blind phase using all patients who were randomized and received at least one dose of study drug through Week 52 and for all patients who received at least one dose of adalimumab during the 10-year study (the Intent-to-Treat [ITT] population).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
Biological: Adalimumab
Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
Biological: Adalimumab
Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
Drug: Placebo
Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
Biological: Adalimumab
Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
Biological: Adalimumab
Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
Biological: Adalimumab
Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
Also known as: ABT-D2E7, Humira
Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
Also known as: ABT-D2E7, Humira
Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
Also known as: ABT-D2E7, Humira
Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
Also known as: ABT-D2E7, Humira
Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
Also known as: ABT-D2E7, Humira
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
Time frame: Week 24
Change From Baseline in Modified Total Sharp X-ray Score at Week 52
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 52. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
Time frame: Baseline and Week 52
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.
Time frame: Baseline and Week 52
Number of Participants Meeting ACR20 Response Criteria at Week 52
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
Time frame: Week 52
Change From Baseline in Modified Total Sharp X-ray Score at Week 24
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 24. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
Time frame: Baseline and Week 24
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 24
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.
Time frame: Baseline and Week 24
Maintenance of the Disability Index of the HAQ at Week 52 for Participants Who Were Responders at Week 12 or Week 24
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Responders had a \>= 0.22-unit decrease (improvement) in HAQ scores from baseline to Week 12 or 24.
Time frame: Week 52
Maintenance of ACR20 Response at Week 52 for Participants Who Were ACR20 Responders at Week 24
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
Time frame: Week 52
Number of Participants With a Continuous ACR70 Response for 6 Months During 52 Weeks of Treatment
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
Time frame: Baseline through Week 52
Time to First Response According to ACR20 Criteria - Number of Participants Meeting ACR20 Criteria for the First Time at Each Time Point
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
Time frame: Baseline through Week 52
Time to First Response According to ACR50 Criteria - Number of Participants Meeting ACR50 Criteria for the First Time at Each Time Point
Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
Time frame: Baseline through Week 52
Time to First Response According to ACR70 Criteria - Number of Participants Meeting ACR70 Criteria for the First Time at Each Time Point
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
Time frame: Baseline through Week 52
Estimated Yearly Progression of Rheumatoid Arthritis
Estimated yearly progression was defined as modified total Sharp x-ray score at baseline divided by duration of rheumatoid arthritis disease at baseline. Actual progression during the study was defined as modified total Sharp x-ray score at Week 52 minus modified total Sharp x-ray score at baseline divided by the duration of the study. The range of scores for the modified total Sharp x-ray score was 0 (normal) to 398 (maximal disease).
Time frame: Baseline and Week 52
Baseline Measure: Gender - Female/Male - for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)
Gender (female/male) recorded at Baseline for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.
Time frame: Baseline for Intent-to-Treat (Any Adalimumab Through Year 10) Group
Baseline Measure: Age Categories for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)
Age recorded at Baseline, reported by category, for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.
Time frame: Baseline for Intent-to-Treat (Any Adalimumab Through Year 10) Group
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
Time frame: Week 260
Number of Participants Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 520
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
Time frame: Week 520
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260
Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
Time frame: Week 260
Number of Participants Meeting the American College of Rheumatology 50% (ACR50) Response Criteria at Week 520
Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
Time frame: Week 520
Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 260
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
Time frame: Week 260
Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 520
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
Time frame: Week 520
Number of Participants With a Continuous American College of Rheumatology 70% (ACR70) Response for at Least 6 Months Through Year 10
Patients were responders if they had: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
Time frame: Baseline through Week 520
Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 260
The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.
Time frame: Week 260
Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 520
The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.
Time frame: Week 520
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.
Time frame: Baseline and Week 260
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.
Time frame: Baseline and Week 520
Change From Baseline in Modified Total Sharp X-ray Score at Week 416
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 416. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
Time frame: Baseline and Week 416
Change From Baseline in Modified Total Sharp X-ray Score at Week 520
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 520. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
Time frame: Baseline and Week 520
Subjects were enrolled at 95 sites in the United States and Canada between February 2000 and August 2001.
| Milestone | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew | DB Adalimumab 20 mg ew/OL Adalimumab 40 mg Eow | DB Adalimumab 40 mg Eow/OL Adalimumab 40 mg Eow | DB Placebo ew/OL Adalimumab 40 mg Eow |
|---|---|---|---|---|---|---|
| Started | 212 | 207 | 200 | 0 | 0 | 0 |
| Completed | 168 | 159 | 140 | 0 | 0 | 0 |
| Not completed | 44 | 48 | 60 | 0 | 0 | 0 |
| Milestone | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew | DB Adalimumab 20 mg ew/OL Adalimumab 40 mg Eow | DB Adalimumab 40 mg Eow/OL Adalimumab 40 mg Eow | DB Placebo ew/OL Adalimumab 40 mg Eow |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 165 | 158 | 134 |
| Completed | 0 | 0 | 0 | 66 | 80 | 56 |
| Not completed | 0 | 0 | 0 | 99 | 78 | 78 |
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24 | 129 | 131 | 59 |
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 52. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
| Units on a scale | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Change From Baseline in Modified Total Sharp X-ray Score at Week 52 | 0.8 ± 4.9 | 0.1 ± 4.8 | 2.7 ± 6.8 |
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Number of Participants Meeting ACR20 Response Criteria at Week 52 | 116 | 122 | 48 |
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 24. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
| Units on a scale | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Change From Baseline in Modified Total Sharp X-ray Score at Week 24 | 0.6 ± 4.9 | 0.3 ± 4.5 | 1.3 ± 3.7 |
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.
| Units on a scale | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 24 | -0.60 ± 0.53 | -0.56 ± 0.52 | -0.24 ± 0.52 |
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.
| Units on a scale | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 | -0.61 ± 0.55 | -0.59 ± 0.57 | -0.25 ± 0.56 |
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Responders had a \>= 0.22-unit decrease (improvement) in HAQ scores from baseline to Week 12 or 24.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Maintained Response | 130 | 121 | 73 |
| Did Not Maintain Response | 7 | 4 | 9 |
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Maintained Response | 99 | 111 | 32 |
| Did Not Maintain Response | 21 | 12 | 23 |
| Missing | 9 | 8 | 4 |
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Number of Participants With a Continuous ACR70 Response for 6 Months During 52 Weeks of Treatment | 20 | 18 | 3 |
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Non-responder | 25 | 29 | 81 |
| Week 2 | 69 | 53 | 26 |
| Week 4 | 48 | 48 | 30 |
| Week 8 | 29 | 33 | 21 |
| Week 12 | 17 | 23 | 14 |
| Week 16 | 7 | 8 | 12 |
| Week 20 | 8 | 7 | 3 |
| Week 24 | 2 | 2 | 7 |
| Week 32 | 4 | 2 | 2 |
| Week 40 | 0 | 2 | 1 |
| Week 48 | 1 | 0 | 2 |
| Week 52 | 2 | 0 | 1 |
Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Non-responder | 71 | 69 | 135 |
| Week 2 | 18 | 13 | 4 |
| Week 4 | 17 | 26 | 6 |
| Week 8 | 26 | 25 | 6 |
| Week 12 | 25 | 21 | 10 |
| Week 16 | 23 | 21 | 8 |
| Week 20 | 16 | 10 | 9 |
| Week 24 | 7 | 7 | 3 |
| Week 32 | 4 | 7 | 8 |
| Week 40 | 3 | 2 | 6 |
| Week 48 | 1 | 3 | 3 |
| Week 52 | 1 | 3 | 2 |
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.
| Participants | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Non-responder | 126 | 120 | 177 |
| Week 2 | 5 | 5 | 2 |
| Week 4 | 5 | 6 | 3 |
| Week 8 | 11 | 7 | 1 |
| Week 12 | 14 | 16 | 2 |
| Week 16 | 15 | 9 | 1 |
| Week 20 | 9 | 11 | 2 |
| Week 24 | 4 | 11 | 2 |
| Week 32 | 9 | 8 | 3 |
| Week 40 | 4 | 4 | 2 |
| Week 48 | 4 | 6 | 3 |
| Week 52 | 6 | 4 | 2 |
Estimated yearly progression was defined as modified total Sharp x-ray score at baseline divided by duration of rheumatoid arthritis disease at baseline. Actual progression during the study was defined as modified total Sharp x-ray score at Week 52 minus modified total Sharp x-ray score at baseline divided by the duration of the study. The range of scores for the modified total Sharp x-ray score was 0 (normal) to 398 (maximal disease).
| Units on a scale | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew |
|---|---|---|---|
| Estimated yearly progression | 11.11 ± 16.75 | 9.46 ± 10.42 | 9.97 ± 12.84 |
| Actual progression during study | 0.77 ± 4.90 | 0.09 ± 4.75 | 2.66 ± 6.73 |
Gender (female/male) recorded at Baseline for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Female | 413 |
| Male | 140 |
Age recorded at Baseline, reported by category, for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| < 40 years | 50 |
| Between 40 and 64 years | 361 |
| Between 65 and 74 years | 117 |
| >= 75 years | 25 |
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
| Participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260 | 200 |
Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 520 | 115 |
Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260 | 153 |
Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants Meeting the American College of Rheumatology 50% (ACR50) Response Criteria at Week 520 | 100 |
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 260 | 87 |
Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 520 | 78 |
Patients were responders if they had: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants With a Continuous American College of Rheumatology 70% (ACR70) Response for at Least 6 Months Through Year 10 | 159 |
The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 260 | 205 |
The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.
| participants | Any Adalimumab Through Year 10 |
|---|---|
| Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 520 | 110 |
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.
| units on a scale | Any Adalimumab Through Year 10 |
|---|---|
| Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260 | -0.56 ± 0.62 |
Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.
| units on a scale | Any Adalimumab Through Year 10 |
|---|---|
| Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520 | -0.62 ± 0.60 |
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 416. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
| units on a scale | DB Adalimumab 20 mg ew/OL Adalimumab 40 mg Eow | DB Adalimumab 40 mg Eow/OL Adalimumab 40 mg Eow | DB Placebo ew/OL Adalimumab 40 mg Eow |
|---|---|---|---|
| Change From Baseline in Modified Total Sharp X-ray Score at Week 416 | 1.16 ± 7.969 | 0.14 ± 9.310 | 4.83 ± 10.012 |
Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 520. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.
| units on a scale | DB Adalimumab 20 mg ew/OL Adalimumab 40 mg Eow | DB Adalimumab 40 mg Eow/OL Adalimumab 40 mg Eow | DB Placebo ew/OL Adalimumab 40 mg Eow |
|---|---|---|---|
| Change From Baseline in Modified Total Sharp X-ray Score at Week 520 | 2.60 ± 8.822 | 0.72 ± 10.430 | 6.18 ± 12.071 |
Collected over For the double-blind (DB) phase: Week 0 to Week 52; for the Any Adalimumab Through Year 10 (intent-to-treat [ITT]) group: first adalimumab injection to the last day in Year 10 (for each subject, the day of the last adalimumab injection plus 70 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Adalimumab 20 mg ew | — | 34/212 (16%) | 167/212 (78.8%) |
| DB Adalimumab 40 mg Eow | — | 27/207 (13%) | 148/207 (71.5%) |
| DB Placebo ew | — | 20/200 (10%) | 149/200 (74.5%) |
| Any Adalimumab Through Year 10 | — | 271/553 (49%) | 511/553 (92.4%) |
| Event | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew | Any Adalimumab Through Year 10 |
|---|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/212 | 0/207 | 1/200 | 35/553 |
| PneumoniaInfections and infestations | 1/212 | 4/207 | 1/200 | 20/553 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/212 | 0/207 | 0/200 | 18/553 |
| CellulitisInfections and infestations | 0/212 | 0/207 | 0/200 | 15/553 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/212 | 0/207 | 0/200 | 13/553 |
| Myocardial infarctionCardiac disorders | 0/212 | 1/207 | 0/200 | 10/553 |
| Atrial fibrillationCardiac disorders | 1/212 | 1/207 | 1/200 | 7/553 |
| Coronary artery diseaseCardiac disorders | 0/212 | 1/207 | 0/200 | 7/553 |
| Hip fractureInjury, poisoning and procedural complications | 0/212 | 1/207 | 0/200 | 7/553 |
| Lobar pneumoniaInfections and infestations | 0/212 | 0/207 | 0/200 | 7/553 |
| Event | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew | Any Adalimumab Through Year 10 |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 35/212 | 35/207 | 22/200 | 225/553 |
| SinusitisInfections and infestations | 21/212 | 22/207 | 17/200 | 150/553 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 10/212 | 14/207 | 24/200 | 123/553 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/212 | 11/207 | 15/200 | 120/553 |
| NasopharyngitisInfections and infestations | 23/212 | 24/207 | 18/200 | 119/553 |
| Injection site painGeneral disorders | 37/212 | 37/207 | 43/200 | 74/553 |
| Urinary tract infectionInfections and infestations | 16/212 | 18/207 | 15/200 | 118/553 |
| HypertensionVascular disorders | 11/212 | 9/207 | 4/200 | 116/553 |
| BronchitisInfections and infestations | 16/212 | 7/207 | 15/200 | 106/553 |
| Back painMusculoskeletal and connective tissue disorders | 15/212 | 10/207 | 9/200 | 103/553 |
| Age, Customized(participants) | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew | Total |
|---|---|---|---|---|
| < 40 years | 10 | 27 | 18 | 55 |
| Between 40 and 64 years | 150 | 115 | 137 | 402 |
| Between 65 and 74 years | 41 | 54 | 35 | 130 |
| >= 75 years | 11 | 11 | 10 | 32 |
| Sex: Female, Male(Participants) | DB Adalimumab 20 mg ew | DB Adalimumab 40 mg Eow | DB Placebo ew | Total |
|---|---|---|---|---|
| Female | 160 | 158 | 146 | 464 |
| Male | 52 | 49 | 54 | 155 |
The record gives a start of Feb 2000, a primary completion of Sep 2002 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 7 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab